2020~Present2019~2000
-
2025
- Mezofy™ Receives U.S. FDA Approval
- Selected for National New Drug Development Project
-
2023
- Animal Dietary Supplement M&A
-
2022
- Launch of CHA&MOM Business
-
2021
- Technology Export of Targeted Anticancer Drug
-
2020
- Grade A in Technology Evaluation for Special Listing
-
2019
- Entry into Consumer Healthcare Business
- Submission of Mezofy™ OF NDA to U.S. FDA
-
2018
- Selected as one of the Financial Times’ Top 1000 Fast-Growing Companies in the Asia-Pacific Region
-
2016
- Mezofy™ OF Successfully Completes U.S. FDA Phase 1 Clinical Trial
- Certified as a Venture Company
-
2015
- Mezofy™ OF Approved for U.S. FDA Clinical Trials
- STARFILM® Patent Filed
- Launch of Film-Type Erectile Dysfunction Treatment ‘Jedaerofil (OF)’
-
2014
- Acquisition of New Drug Development Division (Chemizon)
- April 2014: Established R&D and Business Operations at Pangyo CHA Bio Complex
-
2013
- Company name changed from ‘Sky New Pharm Co., Ltd.’ to ‘CMG Pharmaceuticals Co., Ltd.’
-
2012
- Majority shareholder changed to Cha Bio & Diostech
- Launched medical device business
-
2008
- Commenced manufacturing and sales of pharmaceuticals following the absorption merger of Cellat Pharm Korea Co., Ltd.
-
2007
- Completed construction of PIC/S GMP facility in Siheung-si, Gyeonggi-do
-
2006
- Company name changed to ‘Sky New Pharm Co., Ltd.’
-
2001
- Listed on the KOSDAQ market